Champions Oncology

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Champions Oncology reports Q4 rebound, eyes revenue growth in 2025

Champions Oncology navigated challenges to achieve improved financial performance in Q4. The company is well-positioned with no debt and a cash-neutral strategy for 2025. Management's confidence in long-term prospects signals growth potential.

Champions Oncology (CSBR) reports robust Q1 earnings and growth outlook

Champions Oncology (CSBR) delivered a strong performance in Q1 2025, with revenue surpassing $14 million and notable margin improvements. Despite challenges faced in the past, the company has demonstrated resilience and improvement, positioning itself for future growth. Optimism from management and strategic initiatives highlight a promising outlook for Champions Oncology.

Champions Oncology excels in Q2 2025, eyes new revenue streams

Champions Oncology's Q2 2025 showcased robust financial performance, driven by revenue growth, margin improvement, and cost control measures. While facing challenges in capital needs and competitive pressures, the company's strong fundamentals and strategic initiatives position it well for future opportunities. By leveraging its core strengths and exploring new revenue streams, Champions Oncology aims to sustain its growth trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Champions Oncology, Inc. (NASDAQ:CSBR ) Q4 2023 Earnings Conference Call July 24, 2023 4:30 PM ET Company Participants Ronnie Morris - Chief Executive Officer David Miller - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Scott Henry - ROTH Capital Operator Greetings, and welcome to Champions Oncology's Fourth Quarter and Fiscal Year-End 2023 Earnings Conference Call. At this time, all participants are in listen-only mode.

Champions Oncology, Inc. (CSBR) Q4 2023 Earnings Call Transcript

Record Annual Revenue of $53.9 Million HACKENSACK, NJ / ACCESSWIRE / July 24, 2023 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2023. Fourth Quarter and Fiscal Year 2023 Financial and Recent Business Highlights: Fourth quarter revenue increased 2% to $13.1 million Record annual revenue of $53.9 million, an increase of 10% year-over-year Year-over-year fourth quarter and annual bookings increase of 15% Announced the formation of our wholly owned bio-tech subsidiary, Corellia AI, to develop novel therapeutics Ronnie Morris, CEO of Champions, commented, "Overall we had another year of business expansion, developing our platforms and investing in our drug discovery efforts.

Champions Oncology Reports Quarterly Revenue of $13.1 Million

HACKENSACK, NJ / ACCESSWIRE / July 20, 2023 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the fourth quarter and year ended April 30, 2023, on Monday, July 24, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.

Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 24, 2023

HACKENSACK, NJ / ACCESSWIRE / April 17, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled research organization that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic (PPMO) integration, announced the launch of its therapeutic discovery and development platform into a wholly owned subsidiary named Corellia AI (Corellia). Corellia launches out of Champions Oncology with a team of world class scientists advancing a robust pipeline of therapeutic programs and a unique discovery and development platform.

Champions Oncology Announces the Formation of Corellia AI, a Wholly Owned Biotech that Leverages Unique AI-Enabled Workflows for Novel Therapeutic Development

HACKENSACK, NJ / ACCESSWIRE / April 5, 2023 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $5 million of its common stock through April 30, 2024 pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. Ronnie Morris, CEO of Champions commented, "We are committed to strategically deploying capital to drive long-term value for stockholders.

Champions Oncology Announces $5M Stock Repurchase Program

Champions Oncology, Inc. (NASDAQ:CSBR ) Q3 2023 Earnings Conference Call March 15, 2023 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Matthew Hewitt - Craig-Hallum Operator Good day, everyone, and welcome to the Champions Oncology Third Quarter Fiscal Year 2023 Earnings Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, Dr. Ronnie Morris, Chief Executive Officer of Champions Oncology.

Champions Oncology, Inc. (CSBR) Q3 2023 Earnings Call Transcript

Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -200% and 2.26%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?

Champions Oncology, Inc. (CSBR) Reports Q3 Loss, Tops Revenue Estimates

HACKENSACK, NJ / ACCESSWIRE / March 15, 2023 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its third quarter of fiscal 2023, ended January 31, 2023. Third Quarter and Recent Highlights: Record quarterly bookings Quarterly revenue of $12.8 million Adjusted EBITDA loss of $1.6 million, driven by a $1 million increase in R&D for our target discovery program Commenced in-vivo efficacy testing for therapeutic hits on lead programs Ronnie Morris, CEO of Champions, commented, "Our third quarter results were weaker than we've been accustomed to delivering, impacted primarily by the macro-economic environment.

Champions Oncology Reports Quarterly Revenue of $12.8 Million

HACKENSACK, NJ / ACCESSWIRE / March 13, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the third quarter ended January 31, 2023, on Wednesday, March 15, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.

Champions Oncology to Announce Third Quarter Financial Results on Wednesday, March 15, 2023

CSBR runs a PDX bank. PDXs are mice models of human derived tumors. The company offers services to bio and pharma companies in pre clinical treatment testing. Its test have high predictive power for human results, without the associated cost.

Champions Oncology Trades At A Sufficient Discount To R&D Capacity

Champions Oncology, Inc. (NASDAQ:CSBR ) Q2 2023 Results Conference Call December 13, 2022 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Scott Henry - ROTH Capital Operator Good day, ladies and gentlemen, and welcome to the Champions Oncology Second Quarter Fiscal Year 2023 Earnings Call. At this time, all participants have been placed on a listen-only mode and the floor will be opened for you questions and comments after the presentation.

Champions Oncology, Inc. (CSBR) Q2 2023 Earnings Call Transcript

HACKENSACK, NJ / ACCESSWIRE / December 13, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its second quarter of fiscal 2023, ended October 31, 2022. Second Quarter and Recent Highlights: Record quarterly revenue of $14.3 million, an increase of 21% year over year Adjusted EBITDA of $686,000 Discovery targets progressing along the development timeline; expectation to advance to preclinical phase testing in calendar 2023 Ronnie Morris, CEO of Champions, commented, "We continued to deliver good financial results while simultaneously investing in the future growth of the business.

Champions Oncology Reports Record Quarterly Revenue of $14.3 Million

HACKENSACK, NJ / ACCESSWIRE / December 9, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the second quarter ended October 31, 2022, on Tuesday, December 13, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.

Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 13, 2022

Achieve Life Sciences

Amprius Technologies Inc

Bilibili

Digimarc

Gannett Co.

KalVista Pharma

KLX Energy Services Holdings Inc

System1, Inc

Unity Biotechnology Inc

With the significant volatility and uncertainty in equity markets expected to continue through 2023, some investors are seeking alternative short to medium-term trading ideas.

Fintel's top 10 Gamma Squeeze Stocks For November

Champions Oncology, Inc. (NASDAQ:CSBR ) Q1 2023 Earnings Conference Call September 8, 2022 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Operator Good day, ladies and gentlemen, and welcome to the First Quarter Fiscal Year 2023 Champions Oncology Conference Call [Operator Instructions]. It is now my pleasure to turn the floor over to your host, Ronnie Morris, CEO of Champions Oncology.

Champions Oncology, Inc. (CSBR) Q1 2023 Earnings Call Transcript

Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -300% and 2.27%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?

Champions Oncology, Inc. (CSBR) Reports Q1 Loss, Tops Revenue Estimates

HACKENSACK, NJ / ACCESSWIRE / September 8, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its first quarter of fiscal 2023, ended July 31, 2022. First Quarter and Recent Highlights: Record quarterly revenue of $13.7 million, an increase of 22% year over year Adjusted EBITDA of $450,000 Record quarterly bookings Series of antibody hits established in Alloy Therapeutics partnership Ronnie Morris, CEO of Champions, commented, "We continued to deliver on our long-term vision in the first quarter by growing our service business while investing in transformative opportunities.

Champions Oncology Reports Record Quarterly Revenue of $13.7 Million

HACKENSACK, NJ / ACCESSWIRE / September 6, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the first quarter ended July 31, 2022, on Thursday, September 8, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.

Champions Oncology to Announce First Quarter Financial Results on Thursday, September 8, 2022

Record Annual Revenue of $49.1 Million HACKENSACK, NJ / ACCESSWIRE / July 21, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for the year and fourth fiscal quarter ended April 30, 2022. Fourth Quarter and Fiscal Year 2022 Financial and Recent Business Highlights: Fourth quarter revenue increased 22% to $12.9 million Record annual revenue of $49.1 million, an increase of 20% year-over-year Achieved high end of revenue guidance of 20% Gross margin improved to 52% for fiscal year 2022 Adjusted EBITDA of $3.1 million for fiscal year 2022 Ronnie Morris, CEO of Champions, commented, "Fiscal year 2022 was an outstanding year for Champions as we successfully expanded our business lines while continuing to develop and implement our longer term strategies.

Champions Oncology Reports Quarterly Revenue of $12.9 Million

HACKENSACK, NJ / ACCESSWIRE / July 14, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the fourth quarter ended April 30, 2022, on Thursday, July 21, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.

Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 21, 2022

HACKENSACK, NJ and TORONTO, ON / ACCESSWIRE / May 31, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, and Cyclica Inc. ("Cyclica"), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, announced today a therapeutic development partnership. The partnership will combine two therapeutic targets identified and validated within Champions' Lumin platform with Cyclica's drug discovery platform to establish a new therapeutic program.

Champions Oncology Announces a Partnership with Cyclica to Develop Small Molecule Therapeutics

HACKENSACK, NJ / ACCESSWIRE / May 3, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, announced today that its Lumin Bioinformatics Platform has been selected as a finalist for the ‘Best in Show' Competition at the upcoming Bio-IT World Conference & Expo. The company will present an overview and live demonstration of the platform to judges on May 4th.

Champions Oncology Announces its Lumin Bioinformatics Platform Selected as a Finalist for the 'Best in Show' Competition at Bio-IT World Conference & Expo

Here is how Champions Oncology, Inc. (CSBR) and Gamida Cell (GMDA) have performed compared to their sector so far this year.

Has Champions Oncology, Inc. (CSBR) Outpaced Other Medical Stocks This Year?

Champions Oncology's (CSBR) CEO Ronnie Morris on Q3 2022 Results - Earnings Call Transcript

HACKENSACK, NJ / ACCESSWIRE / March 15, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its third quarter of fiscal 2022, ended January 31, 2022. Third Quarter and Recent Highlights: Record quarterly revenue of $13.2 million, an increase of 22% year over year Reported adjusted EBITDA of $1.5 million Gross margin for the nine months ended January 31, 2022 improved to 52% Signed co-development discovery partnerships with Fannin Innovation Studio and Gigamune Ronnie Morris, CEO of Champions, commented, "Our third quarter results represent an execution of our long term strategy to deliver strong growth in our core business while driving key strategic initiatives forward by investing in therapeutic discovery.

News for Champions Oncology Stock (CSBR)